Fig. 2.

Mean TSPO-PET uptake (global mean-scaled) in each study cohort. Microglia depletion study in mice: A WT mice with microglia depleted by PLX5622 injection (WT PLX5622) and age-matched WT mice with placebo injection (WT Placebo) at 6–9 months of age, B Aβ mouse model (PS2APP) with microglia depleted by PLX5622 injection (PS2APP PLX5622) and age-matched mice with placebo injection (PS2APP Placebo) at 11.5 months of age, C Aβ mouse model (deltaE9) with microglia depleted by PLX5622 injection (deltaE9 PLX5622) and age-matched mice with placebo injection (deltaE9 Placebo) at 6 months of age. D Dysfunctional microglia study in mice: mice with deficient Trem2 gene (Trem2^−/−) and age-matched WT mice at 12 months of age. E Dysfunctional microglia study in an Aβ mouse model (APPPS1): with intact Trem2 (APPPS1 Trem2^+/+) and deficient Trem2 (APPPS1 Trem2^−/−) at 12 months of age. F Study of mouse models at the onset of neuropathology: an Aβ mouse model (App^NL−G−F), a tau mouse model (P301S), and age-matched WT mice at 2–2.5 months of age. G Study of mouse models with moderate neuropathology: two Aβ mouse models (App^NL−G−F and APPPS1), a tau mouse model (P301S), and age-matched WT mice at 5–6 months of age. H Study of a mouse model of acute ischemic stroke: mice 7 days after photothrombotic surgery (Stroke) and sham surgery (Sham) at 2 months of age. I Human AD continuum study: subjects with prodromal AD, AD dementia, age-matched control subjects (CTRL test), and young control subjects used for calculation of the normal synchronicity (CTRL train). n represents the number of subjects; the mean age is shown on the bottom right of each image